DOCSLIB.ORG

344 Part 529—Certain Other Dos- Age Form New Animal

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

§ 529.50 21 CFR Ch. I (4-1-96 Edition) (3) Limitations. Milk taken from ani- caused by susceptible organisms in- mals during treatment and for 36 hours cluding E. coli, Pseudomonas spp., and (three milkings) following the last Klebsiella ssp. treatment must not be used for food. (3) Limitations. For intrauterine infu- Treated animals must not be slaugh- sion in the horse only. Not for use in tered for food use for 28 days following horses intended for food. Federal law the last treatment. Cows with systemic restricts this drug to use by or on the clinical signs caused by mastitis should order of a licensed veterinarian. receive other appropriate therapy [48 FR 9640, Mar. 8, 1983, as amended at 53 FR under the direction of a licensed veteri- 27852, July 25, 1988] narian. Federal law restricts this drug to use by or on the order of a licensed § 529.360 Cephalothin discs. veterinarian. (a) Specifications. Cephalothin discs, [58 FR 58486, Nov. 2, 1993] comply with the requirements of § 460.1 of this chapter. PART 529ÐCERTAIN OTHER DOS- (b) Sponsor. See No. 000986 in AGE FORM NEW ANIMAL DRUGS § 510.600(c) of this chapter. (c) Conditions of use. (1) The discs are Sec. used for determining the in vitro sus- 529.50 Amikacin sulfate intrauterine solu- ceptibility of bacteria to cephaloridine tion. and cephalonium. 529.360 Cephalothin discs. (2) For veterinary laboratory diag- 529.365 Cephapirin sodium for nosis only. intramammary infusion. 529.400 Chlorhexidine tablets and suspen- § 529.365 Cephapirin sodium for sion. intramammary infusion. 529.810 Enflurane. 529.1003 Flurogestone acetate-impregnated (a) Specifications. Each 10-milliliter vaginal sponge. dose contains 200 milligrams of 529.1030 Formalin solution. cephapirin sodium activity in a peanut- 529.1044 Gentamicin sulfate in certain other oil gel. dosage forms. (b) Sponsor. See No. 000856 in 529.1044a Gentamicin sulfate intrauterine § 510.600(c) of this chapter. solution. (c) Related tolerances. See § 556.115 of 529.1044b Gentamicin sulfate solution. this chapter. 529.1115 Halothane. 529.1186 Isoflurane. (d) Conditions of use. (1) The drug is 529.1526 Nifurpirinol capsules. used for the treatment of lactating 529.2090 Salicylic acid. cows having bovine mastitis caused by 529.2464 Ticarcillin powder. susceptible strains of Streptococcus 529.2503 Tricaine methanesulfonate. agalactiae and Staphylococcus aureus. AUTHORITY: Sec. 512 of the Federal Food, (2) Administer one dose into each in- Drug, and Cosmetic Act (21 U.S.C. 360b). fected quarter immediately after the quarter has been completely milked SOURCE: 40 FR 13881, Mar. 27, 1975, unless otherwise noted. out. Do not milk out for 12 hours. Re- peat once only in 12 hours. If improve- § 529.50 Amikacin sulfate intrauterine ment is not noted within 48 hours after solution. treatment, consult your veterinarian. (a) Specifications. Each milliliter of (3) Milk that has been taken from sterile aqueous solution contains 250 animals during treatment and for 96 milligrams of amikacin (as the sul- hours (8 milkings) after the last treat- fate). ment must not be used for food. Treat- (b) Sponsor. See No. 000856 in ed animals must not be slaughtered for § 510.600(c) of this chapter. food until 4 days after the last treat- (c) Conditions of useÐ(1) Amount. Two ment. grams (8 milliliters) diluted with 200 [40 FR 57455, Dec. 10, 1975, as amended at 53 milliliters of sterile physiological sa- FR 27852, July 25, 1988] line per day for 3 consecutive days. (2) Indications for use. For treating genital tract infections (endometritis, metritis, and pyometra) in mares when 344 VerDate 29<JUL>96 12:57 Aug 16, 1996 Jkt 167070 PO 00000 Frm 00340 Fmt 8010 Sfmt 8010 C:\CFR\21V6C1SE.TXT pfrm13 Food and Drug Administration, HHS § 529.1030 § 529.400 Chlorhexidine tablets and muscle relaxants with enflurane; not suspension. for use in horses intended for food; ob- (a) Specification. Each tablet and each serve all customary precautions for use 28-milliliter syringe of suspension con- of vascoconstrictor substances; Federal tain 1 gram of chlorhexidine law restricts this drug to use by or on dihydrochloride.1 the order of a licensed veterinarian. (b) Sponsor. See No. 000856 in [46 FR 18965, Mar. 27, 1981, as amended at 49 § 510.600(c) of this chapter. FR 13494, Apr. 5, 1984] (c) Conditions of useÐ(1) Amount. Place 1 or 2 tablets deep in each uter- § 529.1003 Flurogestone acetate-im- ine horn; or infuse a solution of 1 tab- pregnated vaginal sponge. let disolved in an appropriate amount (a) Specifications. Each vaginal sponge of clean boiled water; or infuse one sy- contains 20 milligrams of flurogestone ringe of suspension into the uterus.1 acetate. (2) Indications for use. For prevention (b) Sponsor. See No. 000014 in or treatment of metritis and vaginitis § 510.600(c) of this chapter. in cows and mares when caused by (c) Conditions of useÐ(1) Indications pathogens sensitive to chlorhexidine for use. For synchronizing estrus/ovula- dihydrochloride.1 tion in cycling adult ewes during their (3) Limitations. Prior to administra- normal breeding season. tion, remove any unattached placental (2) Limitations. Using applicator pro- membranes, any excess uterine fluid or vided, insert sponge into ewe's vagina debris, and carefully clean external 13 days before desired start of breeding. genitalia. Use a clean, sterile insemi- For intravaginal use in sheep only. Do nating pipette for administrating solu- not use in young ewes that have not tions and suspensions. Treatment may had lambs. Use plastic or rubber gloves 1 be repeated in 48 to 72 hours. when handling large numbers of [43 FR 10705, Feb. 23, 1979] sponges to minimize exposure to drug. Do not leave sponge in the vagina for § 529.810 Enflurane. more than 21 days. Ewes must not be (a) Specifications. The drug is a clear, slaughtered for food within 30 days of colorless, nonflammable, nonexplosive sponge removal. liquid. [49 FR 45420, Nov. 16, 1984] (b) Sponsor. See 010019 in § 510.600(c) of this chapter. § 529.1030 Formalin solution. (c) Conditions for useÐ(1) Amount. For induction of surgical anesthesia: 4 to 5 (a) Specifications. Formalin solution percent enflurane (with oxygen) for 10 is an aqueous solution containing ap- to 15 minutes. For maintenance of sur- proximately 37 percent by weight of gical anesthesia: 2.2 to 3.5 percent formaldehyde gas, U.S.P. enflurane (with oxygen). (b) Sponsor. Approval to firms identi- (2) Indications for use. For induction fied in § 510.600(c) of this chapter for use and maintenance of general anesthesia as indicated: in horses. (1) No. 050378 for use as in paragraph (3) Limitations. Administer by inhala- (c) of this section. tion; not for use in horses sensitive to (2) Nos. 049968 and 051212 for use as in halogenated anesthetics; increasing paragraphs (c)(1)(i), (c)(1)(ii), (c)(2)(i), depth of anesthesia may produce mus- (c)(2)(ii), and (c)(3) of this section. cle twitching, particularly about face, (c) Conditions of useÐ(1) Indications neck, and forelimb; not for use in preg- for use. The drug is added to the envi- nant mares, foals or weanlings; use less ronmental water as follows: than usual amounts of nondepolarizing (i) For control of the protozoa: Ichthyophthirius spp., Chilodonella spp., Costia spp., Scyphidia spp., Epistylis 1 These conditions are NAS/NRC reviewed spp., and Trichodina spp.; and the and deemed effective. Applications for these uses need not include effectiveness data as monogenetic trematodes: Cleidodiscus specified by § 514.111 of this chapter, but may spp., Gyrodactylus spp., and require bioequivalency and safety informa- Dactylogyrus spp. on salmon, trout, cat- tion. fish, largemouth bass, and bluegill. 345 VerDate 29<JUL>96 12:57 Aug 16, 1996 Jkt 167070 PO 00000 Frm 00341 Fmt 8010 Sfmt 8010 C:\CFR\21V6C1SE.TXT pfrm13 § 529.1044 21 CFR Ch. I (4-1-96 Edition) (ii) For control of fungi of the family heavy bloom of phytoplankton is Saprolegniaceae on salmon, trout, and present, or when the concentration of esocid eggs. dissolved oxygen is less than 5 milli- (iii) For control of external proto- grams per liter. zoan parasites Bodo spp., Epistylis spp., and Zoothamnium spp. on penaeid [51 FR 11441, Apr. 3, 1986, as amended at 58 FR 59169, Nov. 8, 1993; 59 FR 60076, Nov. 22, shrimp. 1994] (2) Amount. The drug concentrations required are as follows: § 529.1044 Gentamicin sulfate in cer- (i) For control of external parasites tain other dosage forms. on fish: § 529.1044a Gentamicin sulfate intra- Concentration of formalin uterine solution. (microliters per liter) (a) Specifications. Each milliliter of Fish Tanks and Earthen raceways (for ponds (in- the drug contains 50 or 100 milligrams up to 1 hour) definitely) of gentamicin (as the sulfate) in sterile Salmon and trout: aqueous solution. Above 50 ° F ................. Up to 170 ........ 15±25 (b) Sponsor. See Nos. 000061, 000856, Below 50 ° F ................. Up to 250 ........ 15±25 054273, 057561, and 058711 in § 510.600(c) of Catfish, largemouth Up to 250 ........ 1 15±25 bass, and bluegill. this chapter. (c) Conditions of use. (1) The drug is 1 Use the lower concentrations when pond is heavily loaded with fish or phytoplankton. indicated for use for control of bac- terial infections of the uterus in horses (ii) For control of fungi of the (metritis) and as an aid in improving Saprolegniaceae on salmon, trout, and conception in mares with uterine infec- esocid eggs: Apply in constant flow tions caused by bacteria sensitive to water supply of incubating facilities gentamicin. for 15 minutes. Concentration of for- (2) It is administered at a dosage malin used is 1,000 to 2,000 microliters level of 2 to 2.5 grams per day for 3 to per liter.
Recommended publications
  • Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: a Retrospective Study

    Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: a Retrospective Study

    medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252883; this version posted March 12, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license . Title page Outcome of Different Therapeutic Interventions in Mild COVID-19 Patients in a Single OPD Clinic of West Bengal: A Retrospective study Running Title: Mild COVID-19 and the Buffet of Treatments: A case series Sayak Roy1, Shambo Samrat Samajdar2, Santanu K Tripathi3, Shatavisa Mukherjee4, Kingshuk Bhattacharjee5 1. Consultant Physician, Dept. of Internal Medicine, Medica Superspeciality Hospital, Kolkata; ORCID ID: https://orcid.org/0000-0002-6185-9375 2. Senior Resident, Dept of Clinical & Experimental Pharmacology, School of Tropical Medicine, Kolkata. 3. Dean (Academics) and Head, Dept of Pharmacology, Netaji Subhash Medical College & Hospital, Bihta, Patna 4. PhD Research Scholar, Dept of Clinical & Experimental Pharmacology, School of Tropical Medicine, Kolkata. ORCID ID: https://orcid.org/0000-0001-9524-1525 5. Independent Biostatistician, Kolkata Corresponding Author: Dr. Sayak Roy 609, G.T.Road, Battala, Serampore, Hooghly, WB, India; PIN – 712201 Email: [email protected] Words: 1906 Tables: 2 References: 20 Informed Consent and Institutional ethical clearance: Taken Conflicts of interest: None Funding: None Acknowledgement: None Data availability: Available on request with the corresponding author NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2021.03.08.21252883; this version posted March 12, 2021.
  • Exploring the Activity of an Inhibitory Neurosteroid at GABAA Receptors

    Exploring the Activity of an Inhibitory Neurosteroid at GABAA Receptors

    1 Exploring the activity of an inhibitory neurosteroid at GABAA receptors Sandra Seljeset A thesis submitted to University College London for the Degree of Doctor of Philosophy November 2016 Department of Neuroscience, Physiology and Pharmacology University College London Gower Street WC1E 6BT 2 Declaration I, Sandra Seljeset, confirm that the work presented in this thesis is my own. Where information has been derived from other sources, I can confirm that this has been indicated in the thesis. 3 Abstract The GABAA receptor is the main mediator of inhibitory neurotransmission in the central nervous system. Its activity is regulated by various endogenous molecules that act either by directly modulating the receptor or by affecting the presynaptic release of GABA. Neurosteroids are an important class of endogenous modulators, and can either potentiate or inhibit GABAA receptor function. Whereas the binding site and physiological roles of the potentiating neurosteroids are well characterised, less is known about the role of inhibitory neurosteroids in modulating GABAA receptors. Using hippocampal cultures and recombinant GABAA receptors expressed in HEK cells, the binding and functional profile of the inhibitory neurosteroid pregnenolone sulphate (PS) were studied using whole-cell patch-clamp recordings. In HEK cells, PS inhibited steady-state GABA currents more than peak currents. Receptor subtype selectivity was minimal, except that the ρ1 receptor was largely insensitive. PS showed state-dependence but little voltage-sensitivity and did not compete with the open-channel blocker picrotoxinin for binding, suggesting that the channel pore is an unlikely binding site. By using ρ1-α1/β2/γ2L receptor chimeras and point mutations, the binding site for PS was probed.
  • 268 Part 522—Implantation Or Injectable Dosage Form

    268 Part 522—Implantation Or Injectable Dosage Form

    § 520.2645 21 CFR Ch. I (4–1–18 Edition) (ii) Indications for use. For the control 522.82 Aminopropazine. of American foulbrood (Paenibacillus 522.84 Beta-aminopropionitrile. larvae). 522.88 Amoxicillin. 522.90 Ampicillin injectable dosage forms. (iii) Limitations. The drug should be 522.90a Ampicillin trihydrate suspension. fed early in the spring or fall and con- 522.90b Ampicillin trihydrate powder for in- sumed by the bees before the main jection. honey flow begins, to avoid contamina- 522.90c Ampicillin sodium. tion of production honey. Complete 522.144 Arsenamide. treatments at least 4 weeks before 522.147 Atipamezole. main honey flow. 522.150 Azaperone. 522.161 Betamethasone. [40 FR 13838, Mar. 27, 1975, as amended at 50 522.163 Betamethasone dipropionate and FR 49841, Dec. 5, 1985; 59 FR 14365, Mar. 28, betamethasone sodium phosphate aque- 1994; 62 FR 39443, July 23, 1997; 68 FR 24879, ous suspension. May 9, 2003; 70 FR 69439, Nov. 16, 2005; 73 FR 522.167 Betamethasone sodium phosphate 76946, Dec. 18, 2008; 75 FR 76259, Dec. 8, 2010; and betamethasone acetate. 76 FR 59024, Sept. 23, 2011; 77 FR 29217, May 522.204 Boldenone. 17, 2012; 79 FR 37620, July 2, 2014; 79 FR 53136, 522.224 Bupivacaine. Sept. 8, 2014; 79 FR 64116, Oct. 28, 2014; 80 FR 522.230 Buprenorphine. 34278, June 16, 2015; 81 FR 48702, July 26, 2016] 522.234 Butamisole. 522.246 Butorphanol. § 520.2645 Tylvalosin. 522.275 N-Butylscopolammonium. 522.300 Carfentanil. (a) Specifications. Granules containing 522.304 Carprofen. 62.5 percent tylvalosin (w/w) as 522.311 Cefovecin.
  • A Pilot Study of the Safety and Initial Efficacy of Ivermectin for The

    A Pilot Study of the Safety and Initial Efficacy of Ivermectin for The

    ALCOHOLISM:CLINICAL AND EXPERIMENTAL RESEARCH Vol. 40, No. 6 June 2016 A Pilot Study of the Safety and Initial Efficacy of Ivermectin for the Treatment of Alcohol Use Disorder Daniel J. O. Roche, Megan M. Yardley, Katy F. Lunny, Stan G. Louie, Daryl L. Davies, Karen Miotto, and Lara A. Ray Background: Ivermectin (IVM) is an antiparasitic agent that has been shown to reduce alcohol intake in mice, suggesting IVM as a potential treatment for alcohol use disorder (AUD). However, the safety profile of IVM administered in combination with an intoxicating dose of alcohol has not been characterized in humans. Methods: This pilot project sought to provide the first clinical evidence that IVM could be reposi- tioned as an AUD pharmacotherapy by examining (i) the safety of combining IVM (30 mg oral , once a day [QD]) with an intoxicating dose of intravenous alcohol (0.08 g/dl) and (ii) the effects of IVM on alcohol cue-induced craving and subjective response to alcohol. Eleven individuals with AUD partici- pated in a randomized, placebo-controlled, crossover study in which they received the study medica- tion, participated in a cue exposure paradigm followed by intravenous alcohol administration, and remained in an inpatient unit overnight for observation. Results: IVM treatment, versus placebo, did not increase the number or severity of adverse effects during alcohol administration or throughout the visit. However, IVM did not reduce cue-induced crav- ing nor did it significantly affect subjective response to alcohol. Conclusions: These results suggest that IVM (30 mg oral, QD) is safe in combination with an intoxi- cating dose of alcohol, but do not provide evidence that this dose of IVM is effective in reducing alcohol craving or its reinforcing effects.
  • Ivermectin and Human Immunity Protocol ID

    Ivermectin and Human Immunity Protocol ID

    Cover Sheet Clinicaltrials.gov ID NCT03459794 Protocol Ivermectin and human immunity ID#STUDY00005069 Adrian Adrian PI: Primary Contact: Wolstenholme Wolstenholme Submission Initial Study Type: IRB Brooke Harwell Parent Protocol: Coordinator: Review Category: Approved 9/27/2017 Date: Expiration 7/11/2018 Date: Print: STUDY00005069 - Ivermectin and human immunity https://ovpr-click-prod.ovpr.uga.edu/uga-ovpr/ResourceAdministration/P... Date: Monday, November 26, 2018 12:06:50 PM View: SF: Basic Information UGA v2 Section 1 - Basic Information 1. * Title of Study: If the study is/will be funded, the IRB recommends The effects of ivermectin on the normal human matching the title in the funding proposal. immune system 2. * Short Title: This can match the long title or be shortened if your Ivermectin and human immunity project uses an acronym or nickname; however, all system generated lists, searches, and documents (including approval letters) will show the short title. 3. Only UGA faculty and selected staff members (senior Principal Investigator (faculty or senior staff) are eligible to serve as PI. See the policy for staff only - see help): more information: http://research.uga.edu/documents Adrian Wolstenholme /eligibility 4. * Does the Principal Investigator have a See the policy for more information: https://research.uga.edu/docs/policies financial interest related to this /compliance research? Yes No /hso/PP_Financial%20Conflicts%20of%20Interests.pdf 5. If you are not sure if your project needs IRB * Are you requesting determination if review, choose "Yes" in the first question. A form will your project meets the definition of open and provide prompts to guide you through an initial assessment to see if your project needs IRB Yes No human subjects research? review.
  • During Prepartum Period on Mastitis and Postpartum Reproductive Efciency Measurements in Egyptian Baladi Cows

    During Prepartum Period on Mastitis and Postpartum Reproductive Efciency Measurements in Egyptian Baladi Cows

    Impact of treatment with anti-parasitic (Ivermectin) during prepartum period on mastitis and postpartum reproductive eciency measurements in Egyptian Baladi cows Ahmed Ismail Damarany ( [email protected] ) Aswan University Faculty of Agriculture and Natural Resources https://orcid.org/0000-0002-0757-933X Research Article Keywords: Ivermectin, mastitis, postpartum reproductive eciency measurements, Baladi cows Posted Date: August 23rd, 2021 DOI: https://doi.org/10.21203/rs.3.rs-823328/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License Page 1/19 Abstract The current investigation was designed to determine the effect of treatment with anti-parasites (Ivermectin) on mastitis and postpartum reproductive eciency measurements in Egyptian Baladi cows. Twenty-four of the cows included in this study were split into two groups. The rst group (n = 12 cows) was injected two months prepartum with two doses (15 days inter-treatment) of IVOMEC® Plus solution subcutaneously behind the shoulder, 1ml/50kg live body weight as prescribed by the manufacturer, whilst the other group (n = 12 cows) was used as a control group. The present results revealed that the incident rate of mastitis in treated cows’ group was signicantly (P < 0.05) lower (16.7%) than control cows’ group (41.7%). The conception rate in treated cows’ group was signicantly (P < 0.05) higher (66.7%) compared with (33.3%) in control group. The time from calving to conception in treated cows was signicantly (P < 0.05) lower 86.5 ± 11.4 days compared to 123.3 ± 13.2 days in the control group.
  • Crystal Polymorphism and Pseudopolymorphism of Ivermectin

    Crystal Polymorphism and Pseudopolymorphism of Ivermectin

    Crystal polymorphism and pseudopolymorphism of ivermectin Michiel Lucas Josias Grobler B.Pharm. Dissertation submitted in partial fulfilment of the requirements for the degree Magister Scientiae in the Department of Pharmaceutics at the Potchefstroomse Universiteit vir Christelike Hoer Onderwys. Supervisor: Prof. M.M. de Villiers. Co-superviso·rs: Dr. W. Liebenberg. Mr. A.F. Marais. POTCHEFSTROOM 2000 TABLE OF CONTENTS TABLE OF CONTENTS ABSTRACT vii UITTREKSEL ix AIM AND OBJECTIVES xi CHAPTER 1: Veterinary formulation: the influence of animal and environmental factors and the solid state properties of drugs 1.1 Introduction 1 1.2 Veterinary dosage forms 2 1.3 Animal and environmental factors influencing veterinary formulation 3 design 1.3.1 Geographical location 3 1.3.2 Dietary habit 4 1.3.3 Gastrointestinal tract 4 1.3.4 Metabolism 5 1.3.5 Renal excretion 6 1.3.6 Biliary excretion 6 1.3. 7 Skin type 7 1 .3.8 Endocrinology 7 1.3.9 Animal behaviour 7 1.3.10 Drug distribution 7 1.3.11 Age 8 1.3.12 Disease states 9 1.3.13 Residues 9 1.3.14 Single or herd dosing 9 1.3.15 Wild or tame 10 1.3.16 Stability 11 1.4 Solid state properties of drugs that influence veterinary formulation 11 design 1.4.1 Effect of particle size on veterinary drug formulations 12 1.4.1.1 Effect of particle size on dissolution and solubility 12 1.4.1.2 Effect of particle size on suspension stability 13 1.4.1.3 Effect of particle size reduction on drug stability 14 1.4.1.4 Effect of particle size on administration of drugs in feed 14 1.4.2 The effect of crystal forms
  • Interactions with Protease Inhibitors Charts Revised February 2018

    Interactions with Protease Inhibitors Charts Revised February 2018

    www.hiv-druginteractions.org Interactions with Protease Inhibitors Charts revised February 2018. Full information available at www.hiv-druginteractions.org Page 1 of 4 Please note that if a drug is not listed it cannot automatically be assumed it is safe to coadminister. ATV Cobi DRV FPV IDV LPV RTV SQV TPV ATV Cobi DRV FPV IDV LPV RTV SQV TPV Anaesthetics & Muscle Relaxants Antibacterials (continued) Alcuronium Ertapenem Bupivacaine Erythromycin Cisatracurium Ethambutol Desflurane Ethionamide Dexmedetomidine Flucloxacillin Enflurane Gentamicin Ephedrine Imipenem/Cilastatin Halothane Isoniazid Isoflurane Kanamycin Ketamine Levofloxacin Linezolid Nitrous oxide Meropenem Propofol Metronidazole Rocuronium Moxifloxacin Sevoflurane Nitrofurantoin Sufentanil Ofloxacin Suxamethonium (succinylcholine) Para-aminosalicylic acid Tetracaine Penicillins Thiopental for distribution. for Pyrazinamide Tizanidine Rifabutin Vecuronium Rifampicin Analgesics Rifapentine Alfentanil Rifaximin Aspirin Spectinomycin Buprenorphine Streptomycin Celecoxib Sulfadiazine Codeine Telithromycin Tetracyclines
  • Calcium-Engaged Mechanisms of Nongenomic Action of Neurosteroids

    Calcium-Engaged Mechanisms of Nongenomic Action of Neurosteroids

    Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Rebas, Elzbieta, Tomasz Radzik, Tomasz Boczek, and Ludmila Zylinska. 2017. “Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids.” Current Neuropharmacology 15 (8): 1174-1191. doi:10.2174/1570159X15666170329091935. http:// dx.doi.org/10.2174/1570159X15666170329091935. Published Version doi:10.2174/1570159X15666170329091935 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:37160234 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA 1174 Send Orders for Reprints to [email protected] Current Neuropharmacology, 2017, 15, 1174-1191 REVIEW ARTICLE ISSN: 1570-159X eISSN: 1875-6190 Impact Factor: 3.365 Calcium-engaged Mechanisms of Nongenomic Action of Neurosteroids BENTHAM SCIENCE Elzbieta Rebas1, Tomasz Radzik1, Tomasz Boczek1,2 and Ludmila Zylinska1,* 1Department of Molecular Neurochemistry, Faculty of Health Sciences, Medical University of Lodz, Poland; 2Boston Children’s Hospital and Harvard Medical School, Boston, USA Abstract: Background: Neurosteroids form the unique group because of their dual mechanism of action. Classically, they bind to specific intracellular and/or nuclear receptors, and next modify genes transcription. Another mode of action is linked with the rapid effects induced at the plasma membrane level within seconds or milliseconds. The key molecules in neurotransmission are calcium ions, thereby we focus on the recent advances in understanding of complex signaling crosstalk between action of neurosteroids and calcium-engaged events.
  • Naturopathic Physicians Regulation

    Naturopathic Physicians Regulation

    PROPOSED AMENDMENTS – NATUROPATHIC PHYSICIANS REGULATION Health Professions Act NATUROPATHIC PHYSICIANS REGULATION PROPOSED TO REPLACE B.C. REG. 282/2008 Contents 1 Definitions 2 College name 3 Reserved titles 4 Scope of practice 5 Restricted activities 6 Limits or conditions on services and restricted activities 7 Patient relations program 8 Health profession corporations 1 PROPOSED AMENDMENTS – NATUROPATHIC PHYSICIANS REGULATION Definitions 1 In this regulation: "Act" means the Health Professions Act; "compound" means (a) in respect of a drug, to mix with one or more other ingredients, and (b) in respect of a therapeutic diet, to mix two or more ingredients; "dispense" has the same meaning as in the Pharmacy Operations and Drug Scheduling Act, but excludes a sale, as defined in that Act; "drug" means, except in the definition of "substance", a drug (a) specified in Schedule I of the Drug Schedules Regulation, B.C. Reg. 9/98, other than a drug set out in the Schedule of this regulation, or (b) specified in Schedule II of the Drug Schedules Regulation; "enteral instillation" means instillation directly into the gastrointestinal tract; "minor surgery" means a surgical procedure that (a) is performed, for a diagnostic or therapeutic purpose, on a superficial anatomical structure, and (b) does not involve (i) sedation, general anaesthesia or respiratory assistance, or (ii) a material risk to life; "naturopathic medicine" means the health profession in which a person provides the services of prevention, assessment and treatment of an individual's
  • EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices

    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General Notices

    EUROPEAN PHARMACOPOEIA 10.0 Index 1. General notices......................................................................... 3 2.2.66. Detection and measurement of radioactivity........... 119 2.1. Apparatus ............................................................................. 15 2.2.7. Optical rotation................................................................ 26 2.1.1. Droppers ........................................................................... 15 2.2.8. Viscosity ............................................................................ 27 2.1.2. Comparative table of porosity of sintered-glass filters.. 15 2.2.9. Capillary viscometer method ......................................... 27 2.1.3. Ultraviolet ray lamps for analytical purposes............... 15 2.3. Identification...................................................................... 129 2.1.4. Sieves ................................................................................. 16 2.3.1. Identification reactions of ions and functional 2.1.5. Tubes for comparative tests ............................................ 17 groups ...................................................................................... 129 2.1.6. Gas detector tubes............................................................ 17 2.3.2. Identification of fatty oils by thin-layer 2.2. Physical and physico-chemical methods.......................... 21 chromatography...................................................................... 132 2.2.1. Clarity and degree of opalescence of
  • Central and Peripheral Neurotoxic Effects of Ivermectin in Rats

    Central and Peripheral Neurotoxic Effects of Ivermectin in Rats

    FULL PAPER Toxicology Central and Peripheral Neurotoxic Effects of Ivermectin in Rats Saša M TRAILOVIĆ1) and Jelena Trailović NEDELJKOVIĆ2) 1)Faculty of Veterinary Medicine, Department of Pharmacology and Toxicology, University of Belgrade, Bulevar oslobodjenja 18, Belgrade 11000 and 2)Faculty of Veterinary Medicine, Department of Nutrition, University of Belgrade, Bulevar oslobodjenja 18, Belgrade 11000, Serbia (Received 27 September 2010/Accepted 6 December 2010/Published online in J-STAGE 20 December 2010) ABSTRACT. Ivermectin is considered a very safe drug; however, there are reports of toxic effects in particularly sensitive populations or due to accidental overdose. The aim of this study was (1) to further characterize the central and peripheral toxic effects of ivermectin in animals and (2) to determine possible therapeutic strategies for use in cases of ivermectin poisoning. We tested the effects of exper- imental doses of ivermectin previously reported to cause various intensities of CNS depression. However, in our study, ivermectin at 2.5, 5.0 and 7.5 mg/kg i.v. did not produce visible CNS depression in rats and 10 mg/kg resulted in sleepiness and staggering 10 to 40 min after application, while a dose of 15 mg/kg caused CNS depression very similar to general anesthesia. Ivermectin dose-dependently potentiates thiopentone-induced sleeping time in rats. Flumazenil (0.2 mg/kg), the benzodiazepine antagonist, did not affect the action of thiopentone; however, it significantly reduced sleeping time in rats treated with a combination of ivermectin (10 mg/kg) and thiopen- tone (25 mg/kg; from 189.86 45.28 min to 83.13 32.22 min; mean SD).